Chemistry:Pseudophenmetrazine

From HandWiki
Short description: Chemical compound
Pseudophenmetrazine
Pseudophenmetrazine.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC11H15NO
Molar mass177.247 g·mol−1

Pseudophenmetrazine is a psychostimulant compound of the morpholine class. It is the N-demethylated and cis-configured analogue of phendimetrazine as well as the cis-configured stereoisomer of phenmetrazine.[1] In addition, along with phenmetrazine, it is believed to be one of the active metabolites of phendimetrazine, which itself is inactive and behaves merely as a prodrug.[2] Relative to phenmetrazine, pseudophenmetrazine is of fairly low potency, acting as a modest releasing agent of norepinephrine (EC50 = 514 nM), while its (+)-enantiomer is a weak releaser of dopamine (EC50 = 1,457 nM) whereas its (−)-enantiomer is a weak reuptake inhibitor of dopamine (Ki = 2,691 nM);[2][3] together as a racemic mixture with the two enantiomers combined, pseudophenmetrazine behaves overall more as a dopamine reuptake inhibitor (Ki = 2,630 nM),[2][3] possibly due to the (+)-enantiomer blocking the uptake of the (−)-enantiomer into dopaminergic neurons and thus preventing it from inducing dopamine release. Neither enantiomer has any significant effect on serotonin reuptake or release (both Ki = >10,000 nM and EC50 = >10,000 nM, respectively).[2][3]

See also

References

  1. Dictionary of Pharmacological Agents. CRC Press. 1997. p. 1333. ISBN 978-0-412-46630-4. https://books.google.com/books?id=A0THacd46ZsC&pg=PA1333. Retrieved 18 May 2012. 
  2. 2.0 2.1 2.2 2.3 "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain". European Journal of Pharmacology 447 (1): 51–7. June 2002. doi:10.1016/S0014-2999(02)01830-7. PMID 12106802. https://zenodo.org/record/1259577. 
  3. 3.0 3.1 3.2 "Interaction of amphetamines and related compounds at the vesicular monoamine transporter". The Journal of Pharmacology and Experimental Therapeutics 319 (1): 237–46. October 2006. doi:10.1124/jpet.106.103622. PMID 16835371.